Back to top
more

Aurinia Pharmaceuticals (AUPH)

(Delayed Data from NSDQ)

$4.91 USD

4.91
984,064

+0.04 (0.82%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $4.90 -0.01 (-0.20%) 5:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for AUPH

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Aurinia Pharmaceuticals Inc [AUPH]

Reports for Purchase

Showing records 1 - 20 ( 136 total )

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 1

03/01/2024

Company Report

Pages: 5

Aurinia to Repurchase Up to 15% of Shares Under Exemptive Relief; Repurchases Began on February 21; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 2

02/22/2024

Company Report

Pages: 11

Lack of Acquirer Reflects Difficulty in Building LN Market

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 3

02/16/2024

Company Report

Pages: 3

4Q-2023 RESULTS

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 10.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 4

01/08/2024

Industry Report

Pages: 5

New Drug Prices for the New Year; We Highlight Three Recent Price Changes in Our Coverage Universe

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 5

12/22/2023

Industry Report

Pages: 45

2024 TOP IDEAS - Healthcare Sector Review/Preview

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 50.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 6

11/21/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for AUPH 112123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 7

11/03/2023

Daily Note

Pages: 3

Summer Heat Can’t Stop a Summer Beat

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 5.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 8

09/22/2023

Daily Note

Pages: 3

Dr. Robert Foster Joins Aurinia''s Board As Part of Cooperation Agreement Between Aurinia and MKT Capital; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 9

08/07/2023

Company Report

Pages: 9

2Q23 Recap: Second Beat-and-Raise Quarter in a Row; Raise PT to $15

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 10

08/04/2023

Company Report

Pages: 3

2Q BEAT

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 5.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 11

05/05/2023

Company Report

Pages: 4

1Q STRONG

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 5.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 12

05/03/2023

Daily Note

Pages: 4

Aurinia Continues to Expand Commercial Opportunities Globally With Swissmedic Approval of LUPKYNIS; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 13

04/05/2023

Company Report

Pages: 3

Small Biopsy Sub-Study Results Encouraging.

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 5.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 14

03/01/2023

Company Report

Pages: 3

4Q-2022 Results-Financial In Line; Most Forward Predictors Improving

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 5.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 15

03/01/2023

Company Report

Pages: 9

4Q Recap: Encouraging Signs From Revitalized Commercial Execution Efforts; 2023 LUPKYNIS Sales Guidance Maintained

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 16

01/26/2023

Company Report

Pages: 3

ONE DAY...TWO POSITIVE IP EVENTS

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 5.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 17

01/25/2023

Company Report

Pages: 5

LUPKYNIS IP Overhang Removed With New U.S. and European Patents and Sun Pharma Settlement; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 18

01/04/2023

Company Report

Pages: 3

Nice Sunset(tlement).

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 5.00

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 19

11/07/2022

Company Report

Pages: 8

A Reset of Expectations to a Slower Growth Trajectory; Reduce PT to $14

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Aurinia Pharmaceuticals Inc

Industry: Medical - Drugs

Record: 20

11/03/2022

Company Report

Pages: 3

3Q-2022 LUPKYNIS SALES MISS

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 5.00

Research Provided by a Third Party